Ovarian Cancer

NOVA clinical trial data outcomes were superior to the real-world outcomes for niraparib, highlighting the critical need for better understanding of variables impacting poly (ADP-ribose) polymerase (PARP) inhibitor outcomes in clinical practice.
Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant.
In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death.
Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status.
Researchers evaluated the connections between safety and efficacy and rucaparib pharmacokinetic exposure in patients with recurrent ovarian cancer.
In the phase 2 OVARIO study, median progression-free survival (PFS) has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities.
Robotic interval debulking surgery is efficient and safe when treating patients with advanced ovarian cancer who are receiving neoadjuvant chemotherapy.
Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer.
Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant.
In a systematic literature review that extracted data from 50 qualifying clinical trials, PARP inhibitor first-line maintenance improved progression-free survival (PFS) “across the board” versus other maintenance treatments in women with advanced ovarian cancer.
Page 3 of 10
Results 21 - 30 of 93